1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Bullous Pemphigoid - Pipeline Review, H2 2016

Bullous Pemphigoid - Pipeline Review, H2 2016

  • December 2016
  • -
  • Global Markets Direct
  • -
  • 39 pages

Bullous Pemphigoid - Pipeline Review, H2 2016

Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Bullous Pemphigoid – Pipeline Review, H2 2016, provides an overview of the Bullous Pemphigoid (Dermatology) pipeline landscape.

Bullous pemphigoid is a chronic, inflammatory, subepidermal, blistering disease. If untreated, it can persist for monthsor years, with periods of spontaneous remissions and exacerbations. The disease can be fatal, particularly in patientswho are debilitated.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Bullous Pemphigoid – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Bullous Pemphigoid (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bullous Pemphigoid (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Bullous Pemphigoid and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 2 and 1 respectively.

Bullous Pemphigoid (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Bullous Pemphigoid (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Bullous Pemphigoid (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Bullous Pemphigoid (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Bullous Pemphigoid (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Bullous Pemphigoid (Dermatology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Bullous Pemphigoid (Dermatology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Bullous Pemphigoid (Dermatology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table Of Contents

Bullous Pemphigoid - Pipeline Review, H2 2016
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Bullous Pemphigoid Overview 6
Therapeutics Development 7
Pipeline Products for Bullous Pemphigoid - Overview 7
Bullous Pemphigoid - Therapeutics under Development by Companies 8
Bullous Pemphigoid - Pipeline Products Glance 9
Clinical Stage Products 9
Early Stage Products 10
Bullous Pemphigoid - Products under Development by Companies 11
Bullous Pemphigoid - Companies Involved in Therapeutics Development 12
iCo Therapeutics Inc. 12
Immungenetics AG 13
True North Therapeutics Inc 14
TxCell SA 15
Bullous Pemphigoid - Therapeutics Assessment 16
Assessment by Monotherapy Products 16
Assessment by Target 17
Assessment by Mechanism of Action 19
Assessment by Route of Administration 21
Assessment by Molecule Type 22
Drug Profiles 24
bertilimumab - Drug Profile 24
Product Description 24
Mechanism Of Action 24
RandD Progress 24
dimethyl fumarate - Drug Profile 27
Product Description 27
Mechanism Of Action 27
RandD Progress 27
ENTX-BP - Drug Profile 28
Product Description 28
Mechanism Of Action 28
RandD Progress 28
Small Molecules for Dermatology, Immunology, Metabolic and CNS Disorders - Drug Profile 29
Product Description 29
Mechanism Of Action 29
RandD Progress 29
TNT-009 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
RandD Progress 30
Bullous Pemphigoid - Dormant Projects 32
Bullous Pemphigoid - Product Development Milestones 33
Featured News and Press Releases 33
Jun 14, 2016: Immune Pharmaceuticals Expands its Bertilimumab Phase II Clinical Trial in Bullous Pemphigoid to Six Academic Institutions in the United States 33
Nov 09, 2015: Immune Pharmaceuticals Announces FDA Acceptance of Investigational New Drug (IND) Application in the U.S. for Bertilimumab for the Treatment of Bullous Pemphigoid 34
Oct 07, 2015: Immune Pharmaceuticals Submits Investigational New Drug Application in the U.S. for its Lead Product Candidate Bertilimumab for the Treatment of Bullous Pemphigoid 34
Jul 13, 2015: Immune Pharmaceuticals to present bertilimumab at The International Eosinophil Society workshop on Personalized Medicine 35
Jun 25, 2015: Immune Pharmaceuticals Initiates Phase II Clinical Trials With Bertilimumab In Ulcerative Colitis And Bullous Pemphigoid 35
Mar 31, 2015: Immune Pharmaceuticals To Expand Bullous Pemphigoid Clinical Development Plan For Bertilimumab 36
Feb 05, 2015: Immune Pharmaceuticals To Present At The BIO CEO and Investor Conference 37
Dec 09, 2014: CEO Dr. Daniel Teper of Immune Pharmaceuticals to Be Interviewed Live on Clear Channel - iHeart Business Talk Radio - December 9, 2014 37
Jul 30, 2014: Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin 37
Appendix 38
Methodology 38
Coverage 38
Secondary Research 38
Primary Research 38
Expert Panel Validation 38
Contact Us 38
Disclaimer 39




List of Tables
Number of Products under Development for Bullous Pemphigoid, H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Clinical Stage Development, H2 2016 9
Comparative Analysis by Early Stage Development, H2 2016 10
Products under Development by Companies, H2 2016 11
Bullous Pemphigoid - Pipeline by iCo Therapeutics Inc., H2 2016 12
Bullous Pemphigoid - Pipeline by Immungenetics AG, H2 2016 13
Bullous Pemphigoid - Pipeline by True North Therapeutics Inc, H2 2016 14
Bullous Pemphigoid - Pipeline by TxCell SA, H2 2016 15
Assessment by Monotherapy Products, H2 2016 16
Number of Products by Stage and Target, H2 2016 18
Number of Products by Stage and Mechanism of Action, H2 2016 20
Number of Products by Stage and Route of Administration, H2 2016 21
Number of Products by Stage and Molecule Type, H2 2016 23
Bullous Pemphigoid - Dormant Projects, H2 2016 32




List of Figures
Number of Products under Development for Bullous Pemphigoid, H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Clinical Stage Development, H2 2016 9
Comparative Analysis by Early Stage Products, H2 2016 10
Assessment by Monotherapy Products, H2 2016 16
Number of Products by Targets, H2 2016 17
Number of Products by Stage and Targets, H2 2016 17
Number of Products by Mechanism of Actions, H2 2016 19
Number of Products by Stage and Mechanism of Actions, H2 2016 19
Number of Products by Stage and Routes of Administration, H2 2016 21
Number of Products by Molecule Types, H2 2016 22
Number of Products by Stage and Molecule Types, H2 2016 22

Companies Mentioned
iCo Therapeutics Inc.
Immungenetics AG
True North Therapeutics Inc
TxCell SA

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Pipeline Review, H2 2016

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Melanocyte Stimulating Hormone Receptor (Melanocortin ...

Adenosine Receptor A3 (ADORA3) - Pipeline Review, H2 2016

Adenosine Receptor A3 (ADORA3) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Adenosine Receptor A3 (ADORA3) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Adenosine Receptor A3 (ADORA3) - Pipeline Review, H2 2016’, provides in depth analysis on Adenosine Recepto ...

Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - Pipeline Review, H2 2016

Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Adrenocorticotropic Hormone ...


ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.